» Articles » PMID: 22415987

Derivation of Mesenchymal Stem Cells from Human Induced Pluripotent Stem Cells Cultured on Synthetic Substrates

Overview
Journal Stem Cells
Date 2012 Mar 15
PMID 22415987
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Human-induced pluripotent stem cells (hiPSCs) may represent an ideal cell source for research and applications in regenerative medicine. However, standard culture conditions that depend on the use of undefined substrates and xenogeneic medium components represent a significant obstacle to clinical translation. Recently, we reported a defined culture system for human embryonic stem cells using a synthetic polymer coating, poly[2-(methacryloyloxy)ethyl dimethyl-(3-sulfopropyl)ammonium hydroxide] (PMEDSAH), in conjunction with xenogeneic-free culture medium. Here, we tested the hypothesis that iPSCs could be maintained in an undifferentiated state in this xeno-free culture system and subsequently be differentiated into mesenchymal stem cells (iPS-MSCs). hiPSCs were cultured on PMEDSAH and differentiated into functional MSCs, as confirmed by expression of characteristic MSC markers (CD166+, CD105+, CD90+,CD73+, CD31-, CD34-, and CD45-) and their ability to differentiate in vitro into adipogenic, chondrogenic, and osteoblastic lineages. To demonstrate the potential of iPS-MSCs to regenerate bone in vivo, the newly derived cells were induced to osteoblast differentiation for 4 days and transplanted into calvaria defects in immunocompromised mice for 8 weeks. MicroCT and histologic analyses demonstrated de novo bone formation in the calvaria defects for animals treated with iPS-MSCs but not for the control group. Moreover, positive staining for human nuclear antigen and human mitochondria monoclonal antibodies confirmed the participation of the transplanted hiPS-MSCs in the regenerated bone. These results demonstrate that hiPSCs cultured in a xeno-free system have the capability to differentiate into functional MSCs with the ability to form bone in vivo.

Citing Articles

Inhibition of TGF-β signaling enhances osteogenic potential of iPSC-derived MSCs.

Umrath F, Frick S, Wendt V, Naros A, Zimmerer R, Alexander D Sci Rep. 2025; 15(1):7814.

PMID: 40050624 PMC: 11885616. DOI: 10.1038/s41598-025-89370-w.


Induced pluripotent stem cell-derived mesenchymal stem cells: whether they can become new stars of cell therapy.

Wu Z, Su Y, Li J, Liu X, Liu Y, Zhao L Stem Cell Res Ther. 2024; 15(1):367.

PMID: 39415276 PMC: 11484330. DOI: 10.1186/s13287-024-03968-x.


Stem cell-derived extracellular vesicles in the therapeutic intervention of Alzheimer's Disease, Parkinson's Disease, and stroke.

Zhou W, Wang X, Dong Y, Gao P, Zhao X, Wang M Theranostics. 2024; 14(8):3358-3384.

PMID: 38855176 PMC: 11155406. DOI: 10.7150/thno.95953.


Lineage-Specific Mesenchymal Stromal Cells Derived from Human iPSCs Showed Distinct Patterns in Transcriptomic Profile and Extracellular Vesicle Production.

Winston T, Song Y, Shi H, Yang J, Alsudais M, Kontaridis M Adv Sci (Weinh). 2024; 11(28):e2308975.

PMID: 38757640 PMC: 11267277. DOI: 10.1002/advs.202308975.


Scalable manufacture of therapeutic mesenchymal stromal cell products on customizable microcarriers in vertical wheel bioreactors that improve direct visualization, product harvest, and cost.

Haskell A, White B, Rogers R, Goebel E, Lopez M, Syvyk A Cytotherapy. 2024; 26(4):372-382.

PMID: 38363250 PMC: 11057043. DOI: 10.1016/j.jcyt.2024.01.009.


References
1.
Melkoumian Z, Weber J, Weber D, Fadeev A, Zhou Y, Dolley-Sonneville P . Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. Nat Biotechnol. 2010; 28(6):606-10. DOI: 10.1038/nbt.1629. View

2.
Richards M, Fong C, Chan W, Wong P, Bongso A . Human feeders support prolonged undifferentiated growth of human inner cell masses and embryonic stem cells. Nat Biotechnol. 2002; 20(9):933-6. DOI: 10.1038/nbt726. View

3.
Klim J, Li L, Wrighton P, Piekarczyk M, Kiessling L . A defined glycosaminoglycan-binding substratum for human pluripotent stem cells. Nat Methods. 2010; 7(12):989-94. PMC: 2994976. DOI: 10.1038/nmeth.1532. View

4.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View

5.
Rodin S, Domogatskaya A, Strom S, Hansson E, Chien K, Inzunza J . Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. Nat Biotechnol. 2010; 28(6):611-5. DOI: 10.1038/nbt.1620. View